![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Invesco Solar ETF
TAN
The Technology Select Sector SPDR® Fund
XLK
4
VanEck Semiconductor ETF
SMH
5
United States Natural Gas
UNG
US Stock MarketDetailed Quotes
Editas Medicine (EDIT)
- 3.460
- +0.030+0.87%
Close May 29 16:00 ET
- 3.430
- -0.030-0.87%
Post 20:01 ET
530.98MMarket Cap-3.04P/E (TTM)
3.500High3.240Low3.91MVolume3.410Open3.430Prev Close13.21MTurnover2.55%Turnover RatioLossP/E (Static)153.46MShares4.53752wk High119.31P/B530.04MFloat Cap1.66052wk Low--Dividend TTM153.19MShs Float99.950Historical High--Div Yield TTM7.58%Range %0.910Historical Low3.375Avg Price1Lot Size
EDIT Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
EDIT Orderflow
Unit: --
EDIT Orderflow Trend
IntradayDayWeekMonth
No Data
Editas Medicine (EDIT) News
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
Editas Medicine Preclinical Data 'Looks Highly Supportive,' Says Evercore ISI
TD Cowen Remains Bullish on Editas Medicine After 'Compelling Preclinical Data'
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Maintains Target Price $15
Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday
Editas Medicine Raises Capital Through Public Equity Offering
Editas Medicine (EDIT) Stock Forum
$Editas Medicine (EDIT.US)$ Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
GlobeNewswire
3m
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer...
GlobeNewswire
3m
New data demonstrate promising preclinical safety profile and durable LDL-C lowering of ≥90% with single dose of EDIT-401 in non-human primates through ~6 months
CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneer...
I have never had good outcome buying calls because of time decay and the high premium associated with very far out calls.
So now I just focus on high conviction- low price stocks for this strategy. At least I don't have to waste money if the desired outcome is not achieved within the time frame.
So now I just focus on high conviction- low price stocks for this strategy. At least I don't have to waste money if the desired outcome is not achieved within the time frame.
14
3
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)